A bispecific antibody does something conceptually simple and clinically significant: it holds two different antigens at the same time. In the T-cell engager format — which is what the vast majority of approved cancer bispecifics use — one arm binds a tumor antigen and the other binds CD3 on T cells. The result is a forced immune synapse: a T cell dragged into direct contact with a tumor cell, activated by the proximity, and driven to kill. This doesn't require the tumor to have any particular immunogenicity, doesn't require manufacturing the patient's own cells, and can be administered as a standard IV infusion from a batch-produced vial. Six bispecific antibodies are FDA-approved for cancer as of 2026, and the pipeline — particularly for solid tumors — is the most active segment of immuno-oncology drug development.
This article is for informational purposes only and does not constitute medical advice. Bispecific antibody therapy eligibility depends on diagnosis, prior treatment history, and current organ function. Consult your hematologist or oncologist to discuss treatment options and trial eligibility.
Summary
Six bispecific T-cell engagers are FDA-approved: teclistamab (Tecvayli, BCMA×CD3 for RRMM, 63% ORR), talquetamab (Talvey, GPRC5D×CD3 for RRMM, 73% ORR), mosunetuzumab (Lunsumio, CD20×CD3 for follicular lymphoma), glofitamab (Columvi, CD20×CD3 for DLBCL, 35% CR), blinatumomab (Blincyto, CD19×CD3 for ALL), and epcoritamab (Epkinly, CD20×CD3 for DLBCL). Step-up dosing protocols have significantly reduced grade 3+ CRS rates. The 2026 pipeline extends bispecifics to solid tumors (HER2×CD3, EGFR×CD3, DLL3×CD3 for SCLC), NK cell engagers, and FcRH5×CD3 in myeloma. Combination with immunomodulatory drugs (lenalidomide) and checkpoint inhibitors is active in multiple Phase 2/3 trials.
ClinicalMetric Analysis
- The GPRC5D target for talquetamab creates a real on-target/off-tumor toxicity pattern that requires patient counseling before treatment — it's not just an abstract safety consideration. GPRC5D is highly expressed on myeloma cells but is also expressed in hair follicles and keratinocytes. Nail and skin changes (onycholysis, skin dysesthesias, rash) occur in 70–80% of patients and taste changes in 45–60% — both reflecting normal tissue expression of the target. These toxicities are rarely grade 3+ but are present throughout treatment and affect quality of life in ways that standard adverse event grading doesn't fully capture. Talquetamab oncology nurses report that the nail changes are among the most functionally bothersome patient complaints. This is a recurring theme in targeted therapies: the toxicity profile reflects the target's normal tissue expression, and understanding where the target is expressed predicts what to expect.
- Bispecific antibodies and CAR-T are now being sequenced in myeloma, and the optimal order remains unsettled — with implications for which patients should be referred to which specialist first. BCMA-targeting bispecifics (teclistamab) and BCMA-targeting CAR-T (cilta-cel, ide-cel) compete for the same antigen in the same late-line RRMM population. Initial BCMA bispecific use doesn't necessarily preclude subsequent CAR-T if BCMA expression is maintained, but it may reduce CAR-T efficacy if partial antigen downregulation has occurred. GPRC5D bispecific (talquetamab) uses a different antigen and can be used after BCMA-targeted therapy. The practical question for oncologists is: in a patient who has failed ARSI + PI + IMiD, should they receive BCMA bispecific, GPRC5D bispecific, or be referred for CAR-T evaluation? The answer depends on patient fitness, manufacturing logistics, and center expertise — there is no phase 3 head-to-head data to guide this sequencing.
- The CD20×CD3 bispecifics (mosunetuzumab, glofitamab, epcoritamab) face a competitive landscape where the right comparator is autologous CAR-T, not historical chemoimmunotherapy. The glofitamab DLBCL data (35.2% CR, 40% ORR in ≥2 prior lines) is compelling, but DLBCL is also the indication where axi-cel, liso-cel, and tisa-cel have all demonstrated CR rates in the 50–60% range as single agents. For patients who can access CAR-T (adequate performance status, available at a qualified center within an appropriate timeframe), the CAR-T data is stronger in aggregate. The clinical space where bispecifics are most valuable in DLBCL is in patients who fail or can't access CAR-T, or as a bridge therapy before CAR-T manufacturing. This positioning will evolve as head-to-head comparison data accumulates.
The Approved Products: Data and Indications
Teclistamab (Tecvayli, J&J): BCMA×CD3 for RRMM after ≥4 prior lines including PI, IMiD, anti-CD38. MajesTEC-1: 63% ORR, 39.4% sCR/CR, median DOR 18.4 months in 165 patients. Infections are the primary safety concern: grade 3+ infections in 44%, driven by T-cell suppression (the same T cells being activated by the bispecific also become exhausted over time). Prophylactic IVIG is commonly given. Cytopenia monitoring required throughout treatment.
Talquetamab (Talvey, J&J): GPRC5D×CD3 for RRMM after ≥4 prior lines. MonumenTAL-1: ORR 73.6% (biweekly dosing), 33% sCR at 0.4mg/kg biweekly, 35% sCR at 0.8mg/kg weekly. Nail/skin/taste toxicities as described above — distinct from typical bispecific profiles. These are its defining adverse events.
Glofitamab (Columvi, Roche/Genentech): CD20×CD3 for R/R DLBCL after ≥2 prior therapies. NP30179 study: 35.2% CR, 40% ORR. A unique feature is the use of obinutuzumab (anti-CD20 pretreatment) given 7 days before first glofitamab dose to reduce CRS by consuming peripheral B cells before CD3 engagement begins — a pharmacological "priming" step that other bispecifics don't use.
Mosunetuzumab (Lunsumio, Genentech): CD20×CD3 for R/R follicular lymphoma after ≥2 prior lines. GO29781: 80% ORR, 60% CR — in a disease where CR rates with standard chemoimmunotherapy in this setting are typically 30–40%. Mosunetuzumab is given as a fixed-duration course (8 cycles, ~6 months), not indefinitely — a meaningful QoL advantage.
Epcoritamab (Epkinly, AbbVie/Genmab): CD20×CD3 for DLBCL given subcutaneously — a delivery advantage. EPCORE NHL-1: 39% ORR, 34.6% CR in heavily pre-treated patients. SC administration allows outpatient first dosing with monitoring versus hospitalization required for some IV bispecifics.
Step-Up Dosing: Why CRS Rates Have Improved
Early T-cell engager experience with blinatumomab showed high-grade CRS was a serious safety barrier. Step-up dosing protocols — starting at a fraction of the therapeutic dose (e.g., 1/100th to 1/30th), then escalating over 2–3 weeks — have dramatically reduced grade 3+ CRS rates for newer bispecifics. The mechanism is counterintuitive: the low first dose activates a small number of T cells, killing some tumor cells and releasing some cytokines. This sensitizes the system to subsequent doses rather than triggering an uncontrolled cascade. Most approved bispecifics now require in-patient or monitored outpatient observation for the step-up doses, then transition to fully outpatient after the target dose is reached. This step-up requirement affects the practical workflow — typically 2–3 short hospitalizations in the first month.
Solid Tumor Bispecifics: The Active Pipeline
The most active solid tumor bispecific programs in 2026: DLL3×CD3 (tarlatamab, Amgen) for SCLC — approved May 2024 as Imdelltra in previously treated SCLC, ORR 40%, mDOR 9.7 months. A complete responder population is emerging. This is the first bispecific approved for a solid tumor. HER2×CD3 (zenocutuzumab, Merus, bispecific for HER2×HER3 — technically not CD3 but dual-HER family): Phase 2 NRG1 fusion-positive cancers, ORR 34%. EGFR×CD3 (AMG 596, JNJ-6372): Phase 1 in NSCLC, EGFR-mutant, dose-escalation. PSMA×CD3 (xaluritamig, Amgen): Phase 1 mCRPC after multiple prior lines, ORR 37.7% at higher doses. The fundamental challenge for solid tumor bispecifics — T-cell trafficking into the tumor microenvironment, immunosuppression, and antigen heterogeneity — hasn't been solved, but tarlatamab's approval demonstrates it can be worked around in the right tumor histology.
Accessing Bispecific Antibody Trials
Commercial bispecific antibodies (teclistamab, talquetamab, glofitamab, mosunetuzumab, epcoritamab) are available through standard oncology prescribing, though access to RISK EVALUATION AND MITIGATION STRATEGY (REMS) programs applies for some. Clinical trials testing bispecifics in earlier lines, novel combinations (bispecific + lenalidomide, bispecific + CAR-T sequential), and new indications are enrolling at academic medical centers and community oncology practices with trial infrastructure. Eligibility for myeloma bispecific trials typically requires RRMM diagnosis, ≥3 prior lines including PI, IMiD, and anti-CD38, adequate organ function (renal function is specifically evaluated given myeloma's nephrotoxic treatment history), and ECOG PS 0–2. Search ClinicalTrials.gov: "bispecific," "teclistamab," "talquetamab," "glofitamab," "tarlatamab" for currently enrolling studies.